insulin oral (NN1954) / Novo Nordisk - LARVOL DELTA

High Plasma Leptin Levels Are Associated with Low Birth Weight and Disease Severity in People with Recently Diagnosed Type 2 Diabetes (ADA 2024) - "Low BW is associated with elevated plasma leptin levels, potentially contributing to disease severity in people recently diagnosed with T2D."

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • CRP • LEP

"Who’s Afraid of the #InsulinForAllAct, ⁦@novonordisk⁩ ⁦@LillyDiabetes⁩? LFG!!!!!! 💪💪💪 https://t.co/PLnHkFf1Ho" (@Kidfears99)

Metabolic Disorders

The upregulated intestinal folate transporters direct the uptake of ligand-modified nanoparticles for enhanced oral insulin delivery. (PubMed, Acta Pharm Sin B) - "Overall, we emphasize that the upregulated intestinal transporters could direct the uptake of ligand-modified nanoparticles by mediating the endocytosis and intracellular trafficking of ligand-modified nanoparticles via the transporter-mediated pathway. This study may also theoretically provide insightful guidelines for the rational design of transporter-targeted nanoparticles to achieve efficient drug delivery in diverse diseases."

Journal • Diabetes • Metabolic Disorders

"Our recent article on #oral #insulin delivery. Feedback is appreciated @Bioconlimited @kiranshaw @novonordisk @NanomedicineICT @ICTMumbai1933 https://t.co/46fWvRqsBB" (@RatneshICT)

Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review. (PubMed, Diabetes Obes Metab) - "In conclusion, better adherence and persistence in people with T2D is associated with lower rates of microvascular and/or macrovascular outcomes and inpatient hospitalization, and lower or budget-neutral total healthcare expenditure. Education and treatment strategies to address suboptimal adherence and persistence are needed to improve clinical and economic outcomes."

Clinical • HEOR • Journal • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial. (PubMed, Lancet Diabetes Endocrinol) - P2 | "I338 can safely improve glycaemic control in insulin-naive patients with type 2 diabetes with no evidence of a difference compared with insulin glargine, a widely used subcutaneously administered basal insulin. Further development of this particular oral insulin project was discontinued because I338 doses were high and, therefore, production of the required quantities of I338 for wide public use was deemed not commercially viable. Improvement of technologies involved in the product's development is the focus of ongoing research."

Clinical • Journal • P2 data • Diabetes • Hypoglycemia • Immunology • Metabolic Disorders • Type 2 Diabetes Mellitus